Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176970 | 0.91 | HTT (0.67) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL7604913 | 0.90 | HTT (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL6539554 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL13055383 | 0.85 | LMNA (0.80) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL708331 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL6183204 | 0.84 | CTSS (0.49) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL854096 | 0.84 | CTSS (0.68) | LMNASMN1; SMN2HTTCTSSCTSL | |
| SCHEMBL31412747 | 0.82 | HTT (0.59) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| Water SCHEMBL8101580 | 0.82 | LMNA (0.71) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| Benzyl Phenethylcarbamate SCHEMBL27338403 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2HTTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| EP-2225238-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-20070105924-A1 | Vigabatrin bioisoteres and related methods of use | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-10 | — | — | US | disclosed |
| WO-2007035964-A2 | VIGABATRIN BIOISOTERES AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | LMNA 3193/4885SMN1; SMN2 3828/4885HTT 4215/4885 |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | LMNA 4474/4885SMN1; SMN2 2219/4885HTT 1198/4885 |
| US-20070105924-A1 | Vigabatrin bioisoteres and related methods of use | GABRB3, GABRB2, GABRE | LMNA 4616/4885SMN1; SMN2 2340/4885HTT 1447/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | LMNA 4474/4885SMN1; SMN2 2219/4885HTT 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.